Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Resveratrol and inflammation
Final published version, 981 KB, PDF document
Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.
Original language | English |
---|---|
Journal | B B A - Molecular Basis of Disease |
Volume | 1852 |
Issue number | 6 |
Pages (from-to) | 1124-1136 |
Number of pages | 13 |
ISSN | 0925-4439 |
DOIs | |
Publication status | Published - 2015 |
Externally published | Yes |
- Adipose Tissue/drug effects, Animals, Anti-Inflammatory Agents, Non-Steroidal/pharmacology, Clinical Trials as Topic, Humans, Inflammation/drug therapy, Obesity/drug therapy, Stilbenes/pharmacology, Translational Medical Research
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 195591641